The latest trial, involving patients with more than 10% of CD52+ lymphoblasts, focused on the efficacy and safety of the combination of alemtuzumab with chemotherapy for the eradication of MRD in T-ALL patients. The gene discussed is CD52; the disease is acute lymphoblastic leukemia.